Marker Therapeutics is a clinical-stage immuno-oncology company that develops and commercializes T cell-based immunotherapies and peptide-based vaccines to treat various hematological malignancies and solid tumors in the US. Its MultiTAA-specific T cell technology is focused on non-engineered tumor-specific T cells, which identify and kill tumor cells expressing tumor-associated antigens. The company also develops TPIV100/110 and TPIV200, with the former for treating breast and ovarian cancer cells, and the latter now in Phase 2 clinical trial for treating breast and ovarian cancers.